TY - JOUR
T1 - Significance of thrombocytopenia in myelodysplastic syndromes
T2 - Associations and prognostic implications
AU - Al Ameri, Ali
AU - Jabbour, Elias
AU - Garcia-Manero, Guillermo
AU - O'Brien, Susan
AU - Faderl, Stefan
AU - Ravandi, Farhad
AU - Shan, Jianqin
AU - Pierce, Sherry
AU - Cortes, Jorge
AU - Kantarjian, Hagop
PY - 2011/4
Y1 - 2011/4
N2 - Purpose: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). Patients and Methods: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. Results: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 109/L were noted in 65%, and platelets counts <30 × 109/L in 26%. Each platelets count drop below the range of 200 × 109/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 109/L were studied. Platelet cutoffs of 30, 50, and 200 × 109/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. Conclusion: Prognosis in MDS is directly associated with the severity of thrombocytopenia.
AB - Purpose: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS). Patients and Methods: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia. Results: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 109/L were noted in 65%, and platelets counts <30 × 109/L in 26%. Each platelets count drop below the range of 200 × 109/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 109/L were studied. Platelet cutoffs of 30, 50, and 200 × 109/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups. Conclusion: Prognosis in MDS is directly associated with the severity of thrombocytopenia.
KW - Myelodysplastic syndrome
KW - Thrombocytopenia
KW - outcome
UR - http://www.scopus.com/inward/record.url?scp=80052822000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052822000&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2011.03.005
DO - 10.1016/j.clml.2011.03.005
M3 - Article
C2 - 21575929
AN - SCOPUS:80052822000
SN - 2152-2650
VL - 11
SP - 237
EP - 241
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 2
ER -
